| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Hani Hassoun | Q89566940 | ||
| Heather Landau | Q89811711 | ||
| Cara A Rosenbaum | Q91296547 | ||
| Daniel J Weisdorf | Q91562911 | ||
| Steven M Devine | Q102147361 | ||
| Robert Schlossman | Q114300414 | ||
| Ravi Vij | Q114413074 | ||
| David D. Hurd | Q115538665 | ||
| Luis Isola | Q117224760 | ||
| Asad Bashey | Q117224761 | ||
| Brian McClune | Q117224762 | ||
| Vera Hars | Q117224763 | ||
| Craig C Hofmeister | Q38321322 | ||
| Parameswaran Hari | Q42118262 | ||
| Koen van Besien | Q43263315 | ||
| Richard Maziarz | Q50173329 | ||
| Jan S Moreb | Q57013107 | ||
| Philip L McCarthy | Q57556195 | ||
| Maria Teresa Gentile | Q59555040 | ||
| Sergio Giralt | Q66764444 | ||
| Edward A. Stadtmauer | Q85544110 | ||
| Muzaffar Qazilbash | Q87088891 | ||
| Paul G. Richardson | Q87712102 | ||
| Marcelo C Pasquini | Q88910007 | ||
| P2093 | author name string | Chen Jiang | |
| Kouros Owzar | |||
| Thomas Martin | |||
| Thomas C Shea | |||
| Michael Kelly | |||
| Mary M Horowitz | |||
| Charles Linker | |||
| Denise Levitan | |||
| Don A Gabriel | |||
| Elizabeth Bennett | |||
| John Postiglione | |||
| Linda Bressler | |||
| Michele Seiler | |||
| Natalie Scott Callander | |||
| Susan Barry | |||
| P2860 | cites work | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma | Q33344746 | ||
| Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients | Q33387698 | ||
| Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences | Q33710994 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) | Q35483580 | ||
| A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients | Q36466481 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial | Q36725446 | ||
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 | ||
| Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 | ||
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation | Q36969778 | ||
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p | Q42781523 | ||
| Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma | Q43121688 | ||
| A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma | Q43251148 | ||
| How I treat multiple myeloma in younger patients | Q43253809 | ||
| Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients | Q43966198 | ||
| Multiple myeloma and acute myelomonocytic leukemia | Q44452150 | ||
| Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. | Q45911819 | ||
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 | ||
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. | Q53243787 | ||
| Multiple Myeloma | Q56453538 | ||
| Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | Q57903998 | ||
| Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 | ||
| Remission maintenance therapy for multiple myeloma | Q66908314 | ||
| Stem cell leukaemia in myelomatosis | Q71017431 | ||
| Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients | Q73355996 | ||
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
| The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis | Q82160201 | ||
| Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma | Q82331197 | ||
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p | Q82907285 | ||
| Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials | Q84715517 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 1770-1781 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Lenalidomide after stem-cell transplantation for multiple myeloma | |
| P478 | volume | 366 |
| Q39654083 | A case of refractory multiple myeloma with proliferation of large granular lymphocytes by lenalidomide treatment and its association with clinical efficacy |
| Q90351178 | A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity |
| Q36954076 | A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. |
| Q50077385 | A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma |
| Q33421680 | A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer |
| Q92126069 | A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma |
| Q87455016 | A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma |
| Q57027518 | A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma |
| Q36862339 | A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. |
| Q37373159 | A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma |
| Q50860596 | A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. |
| Q36654092 | A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial |
| Q41783731 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide |
| Q38845946 | A review of the venous thrombotic issues associated with multiple myeloma |
| Q38742505 | A systematic review of health-related quality of life in longitudinal studies of myeloma patients. |
| Q51055042 | Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. |
| Q39280739 | Academic, Foundation, and Industry Collaboration in Finding New Therapies |
| Q55261911 | Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. |
| Q90351147 | Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma |
| Q46252693 | Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma |
| Q48154859 | Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure |
| Q38095526 | Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma |
| Q38248293 | Advances in multiple myeloma therapy during two past decades |
| Q38093037 | Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors |
| Q99614032 | African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States |
| Q39174731 | Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work |
| Q85830185 | Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome |
| Q35845298 | Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma |
| Q38154518 | Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any? |
| Q38685796 | Allogeneic stem cell transplantation for multiple myeloma: is there a future? |
| Q52883846 | Allogeneic transplantation for multiple myeloma: yes, no or maybe? |
| Q50036381 | Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle |
| Q33418098 | An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma |
| Q38139989 | An old drug with a new future: bendamustine in multiple myeloma. |
| Q38545607 | An update on the use of lenalidomide for the treatment of multiple myeloma |
| Q91694148 | Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration |
| Q48338656 | Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response |
| Q35591742 | Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration |
| Q38845989 | Antiproliferative and antibacterial activity of some glutarimide derivatives. |
| Q30249790 | Are maintenance and continuous therapies indicated for every patient with multiple myeloma? |
| Q38122624 | Association of response endpoints with survival outcomes in multiple myeloma |
| Q64979558 | Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. |
| Q45067612 | Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. |
| Q38248359 | Autologous hematopoietic cell transplantation: an update for clinicians |
| Q48340932 | Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome |
| Q53112373 | Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. |
| Q36438206 | Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma |
| Q38385465 | Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial |
| Q47307819 | BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee |
| Q34380489 | Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. |
| Q41044036 | Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial |
| Q38543122 | Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient |
| Q36682832 | BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma |
| Q44690816 | Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. |
| Q53130499 | Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. |
| Q51174725 | Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. |
| Q33558161 | Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial |
| Q36907828 | Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial |
| Q47604607 | Bortezomib for the treatment of multiple myeloma. |
| Q58575863 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma |
| Q90117531 | Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis |
| Q55395957 | Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. |
| Q39148797 | CARs in the Lead Against Multiple Myeloma |
| Q34308476 | Can we deconstruct cancer, one patient at a time? |
| Q91792885 | Cardiac ALL: Most Unusual Occurrence of Lenalidomide-associated Acute Lymphoblastic Leukemia with Subsequent Cardiac Involvement |
| Q36852225 | Challenges in multiple myeloma diagnosis and treatment |
| Q34964597 | Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia |
| Q57301093 | Chart review across EU5 in MM post-ASCT patients |
| Q40899348 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial |
| Q90293639 | Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy |
| Q52875785 | Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. |
| Q38578071 | Clinical treatment of newly diagnosed multiple myeloma |
| Q36540781 | Clinical value of molecular subtyping multiple myeloma using gene expression profiling |
| Q93138670 | Clonal evolution in myeloma: a narrow road to remission |
| Q96348568 | Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant |
| Q36018407 | Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells |
| Q87132621 | Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma |
| Q41377364 | Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients |
| Q58729363 | Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study |
| Q91011072 | Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale |
| Q46516118 | Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma |
| Q47164979 | Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation |
| Q38146900 | Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database |
| Q38833540 | Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma |
| Q38740213 | Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents |
| Q38429817 | Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? |
| Q53184429 | Continued role for ASCT in multiple myeloma. |
| Q38145676 | Continuous treatment in multiple myeloma: the future? |
| Q35994520 | Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. |
| Q38249930 | Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques |
| Q51067504 | Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. |
| Q92437778 | Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells |
| Q38218209 | Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. |
| Q38895167 | Current Review on High-Risk Multiple Myeloma |
| Q38087939 | Current approaches for the treatment of multiple myeloma |
| Q41819491 | Current approaches to the initial treatment of symptomatic multiple myeloma |
| Q64065748 | Current status of autologous stem cell transplantation for multiple myeloma |
| Q38209433 | Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. |
| Q38182683 | Current strategies for treatment of relapsed/refractory multiple myeloma |
| Q38412189 | Current therapeutic strategies for multiple myeloma |
| Q38072022 | Current therapeutic strategy for multiple myeloma |
| Q39524467 | Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. |
| Q38617375 | Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy |
| Q38996881 | Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma |
| Q93196233 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma |
| Q89701183 | Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma |
| Q89649146 | Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial |
| Q34555067 | Diagnosis and management of neuropathies associated with plasma cell dyscrasias. |
| Q36254820 | Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011. |
| Q38062037 | Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? |
| Q101226316 | EBV-related lymphoma after long-term daratumumab treatment: a case report |
| Q47562378 | Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time |
| Q104795054 | Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients |
| Q36797893 | Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q26767418 | Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis |
| Q38102892 | Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma |
| Q47149240 | Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes |
| Q39010793 | Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. |
| Q33411708 | Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. |
| Q38139998 | Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma |
| Q40190252 | Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. |
| Q38037600 | Emerging biological insights and novel treatment strategies in multiple myeloma |
| Q41955327 | Emerging stem cell therapies: treatment, safety, and biology |
| Q38732370 | End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma |
| Q43090904 | Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus |
| Q37552008 | European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma |
| Q99240062 | Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy |
| Q49048515 | Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting |
| Q38031989 | Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma |
| Q38167704 | Evidence for compliance with long-term medication: a systematic review of randomised controlled trials |
| Q37417591 | Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications |
| Q38033590 | Evolving therapeutic paradigms for multiple myeloma: back to the future |
| Q35592305 | Expanding role of lenalidomide in hematologic malignancies |
| Q33431175 | Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study |
| Q49388014 | Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance |
| Q50042721 | FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma |
| Q41031177 | Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation |
| Q93082000 | Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network |
| Q26745957 | First line vs delayed transplantation in myeloma: Certainties and controversies |
| Q49989185 | Fixed duration vs continuous therapy in multiple myeloma. |
| Q41557109 | Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method |
| Q36176911 | From evidence to clinical practice in blood and marrow transplantation |
| Q47794767 | From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives |
| Q38413040 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. |
| Q38148272 | Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials |
| Q34345502 | Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. |
| Q47587127 | Guidelines for screening and management of late and long-term consequences of myeloma and its treatment |
| Q84291867 | Haematological cancer: Lenalidomide maintenance--perils of a premature denouement |
| Q35569350 | Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities |
| Q50224356 | Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. |
| Q38936142 | Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study. |
| Q33731691 | Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia |
| Q39063520 | Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies |
| Q48102797 | High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. |
| Q33416028 | High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l |
| Q45059686 | Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. |
| Q38062039 | How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events |
| Q34019581 | How we manage autologous stem cell transplantation for patients with multiple myeloma |
| Q39065368 | IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). |
| Q38065298 | Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. |
| Q39138108 | Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience |
| Q58793871 | Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation |
| Q34325722 | Immunomodulatory drugs in multiple myeloma |
| Q58010072 | Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations |
| Q40210416 | Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance |
| Q35674158 | Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. |
| Q90073192 | Immunotherapy in Multiple Myeloma |
| Q41198089 | Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma |
| Q53591452 | Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. |
| Q38691698 | Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study |
| Q42399849 | Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point |
| Q89479386 | Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM |
| Q90593749 | Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry |
| Q36115680 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. |
| Q37570630 | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study |
| Q87812059 | Improved survival with salvage autologous stem-cell transplantation in myeloma |
| Q38387292 | Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. |
| Q91016714 | Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. |
| Q46754093 | Integration of Novel Agents into the Care of Patients with Multiple Myeloma |
| Q38832525 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma |
| Q38157532 | International Myeloma Working Group recommendations for global myeloma care |
| Q47287683 | Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies |
| Q38724650 | Is it possible to cure myeloma without allogeneic transplantation? |
| Q91259625 | Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma? |
| Q38542172 | Ixazomib for the treatment of multiple myeloma. |
| Q36115686 | Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years |
| Q36848023 | Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma |
| Q38662385 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis |
| Q33416468 | Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials |
| Q87287555 | Lenalidomide and second malignancies in myeloma patients |
| Q46408789 | Lenalidomide and secondary acute lymphoblastic leukemia: a case series |
| Q36351120 | Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis |
| Q36145310 | Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma |
| Q37449333 | Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. |
| Q51656403 | Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis. |
| Q33403183 | Lenalidomide for the treatment of relapsed and refractory multiple myeloma. |
| Q54117845 | Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro. |
| Q47418005 | Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against |
| Q34656086 | Lenalidomide in multiple myeloma-a practice guideline |
| Q51071262 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. |
| Q37282307 | Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. |
| Q84937882 | Lenalidomide maintenance in myeloma |
| Q60923162 | Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial |
| Q21133524 | Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials |
| Q104795014 | Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma |
| Q52577558 | Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma. |
| Q52716089 | Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. |
| Q38852886 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. |
| Q38379791 | Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. |
| Q40234452 | Lenalidomide-induced eosinophilic pneumonia |
| Q38632778 | Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. |
| Q38450335 | Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation |
| Q38555091 | Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma |
| Q55285098 | Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials. |
| Q35077901 | Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome |
| Q61803948 | Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma |
| Q37228026 | Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. |
| Q35630256 | Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma |
| Q34399099 | Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. |
| Q38637962 | Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. |
| Q27011282 | Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea |
| Q56376437 | Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis |
| Q88437500 | Maintenance lenalidomide after transplantation: How much is enough? |
| Q42323127 | Maintenance therapy in multiple myeloma |
| Q38191975 | Maintenance therapy in newly diagnosed multiple myeloma: current recommendations |
| Q34973992 | Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials |
| Q30275382 | Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma |
| Q38970595 | Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma |
| Q38874675 | Management of high-risk Myeloma: an evidence-based review of treatment strategies |
| Q49989009 | Management of multiple myeloma in the newly diagnosed patient. |
| Q38896473 | Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. |
| Q38605484 | Managing multiple myeloma in elderly patients |
| Q38233988 | Mathematical modeling for novel cancer drug discovery and development |
| Q44469916 | Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma |
| Q39185604 | Mechanisms of Resistance in Multiple Myeloma |
| Q90428313 | Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents |
| Q26768653 | Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment |
| Q42320398 | Minimal residual disease in multiple myeloma |
| Q36076716 | Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation |
| Q38756800 | Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes |
| Q37373292 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. |
| Q94938284 | Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study |
| Q35886589 | Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study |
| Q36963203 | Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology |
| Q55119496 | Multiple Myeloma: Diagnosis and Treatment. |
| Q56657250 | Multiple myeloma |
| Q86407303 | Multiple myeloma |
| Q49792009 | Multiple myeloma associated with myeloid tumor: 5 cases report and literatures review |
| Q100316249 | Multiple myeloma current treatment algorithms |
| Q38176293 | Multiple myeloma maintenance therapy: a review of the pharmacologic treatment |
| Q36868632 | Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States |
| Q51643779 | Multiple myeloma--translation of trial results into reality. |
| Q44977303 | Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management |
| Q26998884 | Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management |
| Q37623809 | Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management |
| Q58565204 | Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management |
| Q38155425 | Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy |
| Q44470007 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q39471739 | Multiple myeloma: an update |
| Q38572771 | Myeloma Propagating Cells, Drug Resistance and Relapse |
| Q36470699 | Myeloma today: Disease definitions and treatment advances |
| Q29248394 | National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms |
| Q38191867 | New approaches to management of multiple myeloma. |
| Q35177465 | New cancers after autotransplantations for multiple myeloma |
| Q38162911 | New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials |
| Q38673764 | New pharmacotherapy options for multiple myeloma |
| Q38981247 | Next-generation multiple myeloma treatment: a pharmacoeconomic perspective |
| Q39234159 | Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics |
| Q38261677 | Novel agents and new therapeutic approaches for treatment of multiple myeloma. |
| Q26822754 | Novel agents for multiple myeloma to overcome resistance in phase III clinical trials |
| Q33886073 | Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents |
| Q38069614 | Novel immunomodulatory compounds in multiple myeloma |
| Q55332380 | One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. |
| Q28077567 | Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice |
| Q34551324 | Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist |
| Q38833534 | Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation |
| Q38062036 | Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma |
| Q90461504 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial |
| Q38640514 | Oral ixazomib maintenance therapy in multiple myeloma. |
| Q90461493 | Oral proteasome inhibitor maintenance for multiple myeloma |
| Q39379927 | Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation |
| Q38605030 | Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation |
| Q36834629 | Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation |
| Q39158096 | Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma |
| Q34316156 | Patient with refractory multiple myeloma developing eosinophilia after lenalidomide treatment and lung cancer 9 months later: case report and review of the literature |
| Q93000334 | Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma |
| Q38100588 | Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center |
| Q36973705 | Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics |
| Q38108391 | Perspectives in the treatment of multiple myeloma |
| Q38130301 | Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. |
| Q89777624 | Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation |
| Q49988870 | Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. |
| Q50149181 | Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma |
| Q44512399 | Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma |
| Q33410297 | Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma |
| Q33956990 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group |
| Q46617753 | Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance |
| Q41559549 | Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents |
| Q33816582 | Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study |
| Q39388200 | Pomalidomide in the treatment of relapsed multiple myeloma |
| Q34694749 | Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma |
| Q48013706 | Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review. |
| Q84938004 | Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population |
| Q89088825 | Post-transplant therapy in multiple myeloma: a hung jury? |
| Q37737800 | Posttransplant maintenance therapy in multiple myeloma: the changing landscape |
| Q92572416 | Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant |
| Q52801394 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. |
| Q88797028 | Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies |
| Q93184553 | Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs |
| Q37431934 | Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction |
| Q92039526 | Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy |
| Q90950107 | Prognosis value of RBBP8 expression in plasma cell myeloma |
| Q38462720 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy |
| Q33621587 | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma |
| Q44694137 | Progress and Paradigms in Multiple Myeloma |
| Q48178842 | Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft |
| Q40562696 | Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma |
| Q42581682 | Promising therapies in multiple myeloma |
| Q92921561 | Proteasome Inhibitors for the Treatment of Multiple Myeloma |
| Q91559627 | RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation |
| Q61755948 | Radionuclide Therapy of Leukemias and Multiple Myeloma |
| Q37737795 | Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis |
| Q35999062 | Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla |
| Q64287044 | Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma |
| Q88657335 | Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival |
| Q53123065 | Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. |
| Q39405882 | Recent advances in hematopoietic stem cell transplantation. |
| Q28074521 | Recent advances in multiple myeloma: a Korean perspective |
| Q28070331 | Recent advances in understanding multiple myeloma |
| Q89777843 | Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States |
| Q48250743 | Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant. |
| Q52609413 | Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP |
| Q91386824 | Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells |
| Q89602885 | Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial |
| Q49830211 | Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. |
| Q40273400 | Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin |
| Q49391414 | Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. |
| Q30650394 | Review of health-related quality of life data in multiple myeloma patients treated with novel agents |
| Q43916698 | Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? |
| Q36907852 | Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma |
| Q36912632 | Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients |
| Q45713577 | Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide |
| Q40912690 | Risk of skin cancer in multiple myeloma patients: a retrospective cohort study |
| Q37524970 | Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists |
| Q30240206 | Role of stem cell transplant and maintenance therapy in plasma cell disorders. |
| Q97643311 | Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE |
| Q30416452 | Salvage second hematopoietic cell transplantation in myeloma |
| Q44366982 | Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study |
| Q90080640 | Second malignancies in multiple myeloma; emerging patterns and future directions |
| Q39034157 | Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. |
| Q24610430 | Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance |
| Q36557015 | Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma |
| Q43155846 | Second primary malignancies and myeloma therapy: fad or fact? |
| Q39013620 | Second primary malignancies in multiple myeloma: an overview and IMWG consensus |
| Q30756778 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data |
| Q88118095 | Second transplant as a standard for multiple myeloma |
| Q37108758 | Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report |
| Q38933428 | Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance |
| Q37609434 | Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients |
| Q39576312 | Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited |
| Q39027826 | Sequencing of nontransplant treatments in multiple myeloma patients with active disease |
| Q52718973 | Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. |
| Q55091245 | Short overview on the current standard of treatment in newly diagnosed multiple myeloma. |
| Q89777982 | Should minimal residual disease negativity be the end point of myeloma therapy? |
| Q40845932 | Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial |
| Q87870251 | Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma |
| Q26996579 | Smoldering multiple myeloma requiring treatment: time for a new definition? |
| Q38151230 | Smoldering multiple myeloma: present position and potential promises |
| Q38183871 | Staging and prognostication of multiple myeloma |
| Q39410899 | Standardisation of minimal residual disease in multiple myeloma |
| Q36852229 | Stem cell transplantation for multiple myeloma: current and future status |
| Q38688055 | Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). |
| Q91672350 | Stem-cell transplantation in multiple myeloma: how far have we come? |
| Q40647620 | Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide |
| Q37094962 | Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. |
| Q42223210 | Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient |
| Q36436758 | T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy |
| Q39933810 | Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. |
| Q87842402 | Targeting MYC in multiple myeloma |
| Q47775860 | Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study). |
| Q36444523 | Thalidomide and its analogues in the treatment of Multiple Myeloma |
| Q89088785 | Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 |
| Q33956871 | Thalidomide-a notorious sedative to a wonder anticancer drug |
| Q38074017 | Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. |
| Q26822700 | The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies |
| Q26740251 | The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation |
| Q37150733 | The Diagnosis and Treatment of Multiple Myeloma |
| Q37644252 | The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma |
| Q37517482 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia |
| Q53619518 | The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. |
| Q40813914 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. |
| Q45300898 | The devil is in the details: confidentiality challenges in the age of genetics |
| Q40669032 | The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial |
| Q38182679 | The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients |
| Q52715329 | The evolution of stem-cell transplantation in multiple myeloma. |
| Q33917164 | The future of autologous stem cell transplantation in myeloma |
| Q36962747 | The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) |
| Q92355045 | The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells |
| Q38192044 | The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. |
| Q57903975 | The impact of long-term lenalidomide exposure on the cellular composition of bone marrow |
| Q36301512 | The novel mechanism of lenalidomide activity. |
| Q64967112 | The pharmacologic management of multiple myeloma in older adults. |
| Q38685108 | The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma |
| Q38462594 | The risk of secondary primary malignancies after therapy for multiple myeloma |
| Q38200143 | The role of P-glycoprotein in drug resistance in multiple myeloma |
| Q28071644 | The role of maintenance therapy in multiple myeloma |
| Q38375463 | The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q38231358 | The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. |
| Q38749362 | The safety of pomalidomide for the treatment of multiple myeloma |
| Q47135094 | The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma: An 18-year follow-up case report |
| Q38252583 | Therapeutic advancements in multiple myeloma |
| Q39177792 | Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy |
| Q57904303 | Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents |
| Q90317707 | Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras |
| Q38970603 | Transplantation for Multiple Myeloma |
| Q26851202 | Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers |
| Q37037265 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group |
| Q64068728 | Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide |
| Q38316150 | Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. |
| Q37373269 | Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies |
| Q46467958 | Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. |
| Q36960349 | Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. |
| Q42737828 | Trial Watch: Lenalidomide-based immunochemotherapy |
| Q37615593 | Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience |
| Q52841629 | United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. |
| Q46779037 | United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. |
| Q38178031 | Update on second primary malignancies in multiple myeloma: a focused review |
| Q42357639 | Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma |
| Q90260889 | Update on the role of lenalidomide in patients with multiple myeloma |
| Q95641865 | Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide |
| Q38371861 | Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial |
| Q40543905 | Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency |
| Q64900417 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. |
| Q50438558 | Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy |
| Q28544663 | Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma |
| Q38115226 | VI. Autologous stem cell transplantation and maintenance therapy |
| Q43759174 | VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. |
| Q37128664 | Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients |
| Q34283333 | Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. |
| Q33428591 | Venous thromboembolism in hematopoietic stem cell transplant recipients |
| Q92492516 | Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis |
| Q48921667 | When to recommend a second autograft in patients with relapsed myeloma? |
| Q38491721 | When to recommend allogeneic transplant in multiple myeloma |
| Q58023753 | Zielgerichtete Therapien bei hämatologischen Erkrankungen |
| Q87923074 | [Clincal features and treatment of multiple myeloma] |
| Q57024673 | is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice |
Search more.